{'fraction_non_alphanumeric': 0.02050326188257223, 'fraction_numerical': 0.0027958993476234857, 'mean_word_length': 5.172413793103448, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests

Lung cancer is the most common cause of cancer death in the USA. Patients with early-stage non-small-cell lung cancer have a 5-year survival of approximately 70%. Effective, accurate and clinically relevant prognostic tests are needed to determine which patients are at high risk of disease-specific mortality after surgical resection. Currently, there are two commercially available prognostic tests based on differential gene expression for this purpose: the Myriad myPlan™ Lung Cancer and Pervenio™ Lung RS tests. One stratifies patients into two risk groups and the other into three risk groups. Both have been validated in independent patient cohorts and neither has yet been demonstrated to improve survival. These tests have the potential to risk-stratify which patients with early-stage lung cancer will have a higher likelihood of disease recurrence after surgical resection and may benefit from adjuvant treatment.